Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$0.33 - $0.74 $10 - $23
-32 Reduced 6.44%
465 $0
Q3 2023

Nov 13, 2023

BUY
$0.67 - $0.85 $1 - $1
2 Added 0.4%
497 $0
Q2 2023

Aug 15, 2023

SELL
$0.45 - $0.89 $141 - $279
-314 Reduced 38.81%
495 $0
Q1 2023

May 12, 2023

BUY
$0.56 - $0.8 $1 - $2
3 Added 0.37%
809 $0
Q4 2022

Feb 13, 2023

BUY
$0.54 - $0.68 $1 - $2
3 Added 0.37%
806 $0
Q3 2022

Nov 14, 2022

SELL
$0.55 - $0.74 $0 - $0
-1 Reduced 0.12%
803 $0
Q2 2022

Aug 12, 2022

BUY
$0.57 - $1.0 $120 - $212
212 Added 35.81%
804 $0
Q3 2021

Nov 15, 2021

SELL
$0.93 - $1.54 $189 - $314
-204 Reduced 25.63%
592 $0
Q1 2021

May 13, 2021

BUY
$1.56 - $2.7 $499 - $864
320 Added 67.23%
796 $1,000
Q4 2020

Feb 09, 2021

BUY
$0.8 - $2.56 $6 - $20
8 Added 1.71%
476 $0
Q3 2020

Nov 05, 2020

SELL
$0.79 - $1.52 $275 - $530
-349 Reduced 42.72%
468 $0
Q2 2020

Aug 13, 2020

SELL
$0.68 - $1.13 $29,686 - $49,332
-43,657 Reduced 98.16%
817 $0
Q1 2020

May 14, 2020

BUY
$0.78 - $1.95 $34,689 - $86,724
44,474 New
44,474 $41,000

Others Institutions Holding AGE

# of Institutions
1
Shares Held
1K
Call Options Held
0
Put Options Held
0

About AgeX Therapeutics, Inc.


  • Ticker AGE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,945,100
  • Description
  • AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...
More about AGE
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.